GDUFA Stakeholder Deadline May Come After Negotiations Conclude
This article was originally published in The Pink Sheet Daily
Generic drug user fee reauthorization talks remain on schedule and are expected to last about four months.
You may also be interested in...
Kathleen Uhl's five-month leave for cancer treatment ends as user fee negotiations move towards formal start.
Fourth consecutive month of strong results suggests generic review function is back on track.
New policy allows more FDA staffers to answer certain questions about pending applications, rather than channeling them all through the regulatory project manager.